LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Suzhou Amerigen Pharmaceuticals Co., Enters Into a Marketing and Distribution Agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd.

Suzhou Amerigen Pharmaceuticals Co., has entered into a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd. regarding Amerigen’s generic mecobalamin 0.5mg immediate release tablets. Under the terms of the agreement, Amerigen will manufacture the product at its US FDA approved and China CFDA certified finished solid dose facility in Suzhou, China.

Sinochem is granted exclusive sales and distribution rights to the product in the People’s Republic of China in exchange for undisclosed payments to Amerigen. The first commercial shipments of the product, which will be sold under Suzhou Amerigen’s label, are expected in mid-2014. In addition, the parties will seek any regulatory approvals required for the commercialization of the product in China under the terms of the new collaboration arrangement.

John Lowry, Amerigen’s President and CEO, commented: “This agreement is a continuation of our strategy to bring high quality and locally manufactured generic products to the rapidly growing Chinese market by leveraging Amerigen’s FDA and CFDA licensed manufacturing facility in Suzhou. Our collaboration with Sinochem enables expedited market entry through the sales expertise of a highly reputable and leading Chinese pharmaceutical company.”

Mr. Ziqiang Wu, General Manager of Sinochem Pharma, stated: “Sinochem Pharma, the key subsidiary of Sinochem Group – one of the largest companies in the China ‘Fortune 500’, is pleased to cooperate with Amerigen, a renowned pharmaceutical company in China which has passed on-site inspections by the US FDA and China CFDA. We will commit to work together, realize complementary advantages and promote drug products of high quality manufactured by Amerigen in the Chinese market through our joint efforts. The mecobalamin tablet project is just the beginning of the cooperation between our two companies, and we will discuss further business collaborations in the future.”

Click here for the complete issue.


Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy